Roderick C.N. van den Bergh

Dr. Roderick C.N. van den Bergh


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in European Urology
Verified
Journal Article
Closed access
RBRoderick C.N. van den Bergh
Roderick C.N. van den Bergh
PAPeter C. Albertsen
Peter C. Albertsen
CBChris H. Bangma
Chris H. Bangma
SFStephen J. Freedland
Stephen J. Freedland
MGMarkus Graefen
Markus Graefen
HPHenk G. van der Poel
Henk G. van der Poel

1 June 2014 in European Urology
Verified
Journal Article
Closed access
RBRoderick C.N. van den Bergh
Roderick C.N. van den Bergh
HAHashim U. Ahmed
Hashim U. Ahmed
CBChris H. Bangma
Chris H. Bangma
MCMatthew R. Cooperberg
Matthew R. Cooperberg
AVArnauld Villers
Arnauld Villers
CPChristopher C. Parker
Christopher C. Parker

1 May 2012 in Current Opinion in Urology
Verified
Journal Article
Closed access
RBRoderick C.N. van den Bergh
Roderick C.N. van den Bergh
IKIda J. Korfage
Ida J. Korfage
CBChris H. Bangma
Chris H. Bangma
Active surveillance is emerging as a serious alternative to radical therapy for low-risk prostate cancer. In a situation in which the difference in effects on disease morbidity and mortality of different treatment options for these malignancies is likely to be small, the quality of life and psychological aspects may be decisive in treatment choice. The following three are the main issues being covered in the literature on psychological aspects of active surveillance. First, the process of consultation with the physician and treatment choice in men diagnosed with low-risk prostate cancer. Second, the effect of active surveillance on physical domains and resulting anxiety and distress, and on quality of life in general. And third, the possible supportive and educational interventions for patients on active surveillance. Observations are scarce and derived from nonrandomized studies with a limited follow-up after diagnosis. At the moment of treatment choice, fear of disease progression is the main reason to reject active surveillance. Active surveillance may spare physical domains and does not cause much anxiety or distress on short term in men who choose this strategy. Once men opt for active surveillance, only a minority of them switch to radical treatment due to psychological reasons. Supportive and educational interventions should be considered.

1 March 2019 in European Urology Focus
Verified
Journal Article
Closed access
RBRoderick C.N. van den Bergh
Roderick C.N. van den Bergh
GGGiorgio Gandaglia
Giorgio Gandaglia
DTDerya Tilki
Derya Tilki
HBHendrik Borgmann
Hendrik Borgmann
POPiet Ost
Piet Ost
GPGuillaume Ploussard
Guillaume Ploussard

19 January 2012 in BJU International
Verified
Journal Article
Open access
PDF file
RBRoderick C.N. van den Bergh
Roderick C.N. van den Bergh
IKIda J. Korfage
Ida J. Korfage
MRMonique J. Roobol
Monique J. Roobol
CBChris H. Bangma
Chris H. Bangma
HKHarry J. de Koning
Harry J. de Koning
MEMarie‐Louise Essink‐Bot
Marie‐Louise Essink‐Bot
Study Type – Outcomes (cohort sample) Level of Evidence 2b What's known on the subject? and What does the study add? The study compares the sexual function of men with low‐risk prostate cancer who chose active surveillance (expectant management) with similar men who received radiation therapy or radical prostatectomy. The first group appeared to be sexually active more frequently and had less erectile dysfunction. The study was non‐randomized. No other studies exist on the effect of active surveillance on sexual function vs other treatment methods. OBJECTIVE: To compare sexual function of men with localized prostate cancer (PCa) on active surveillance (AS) with similar patients who received radical therapy. PATIENTS AND METHODS: Two groups of men with screening‐detected localized PCa were compared. The first were men on AS within the prospective protocol‐based Prostate Cancer Research International: Active Surveillance study. The second were men participating in the European Randomized Study of Screening for Prostate Cancer study who had received radical prostatectomy (RP) or radiation therapy (RT). Questionnaires were completed at two different timepoints after diagnosis or treatment (6 and 12–18 months). These contained 10 items on sexual function, the mental and physical component summary from the Short‐Form 12‐item health survey, the Center for Epidemiologic Studies Depression scale depression measure and the State Trait Anxiety Inventory general anxiety measure. Sexual function was compared between groups, and determinants were analysed in multivariable analysis, adjusting for baseline differences. RESULTS: A total of 65–68% of men on AS, 35–36% of those who underwent RP, 36–37% of those who underwent RT and 36% of men in the RP and RT groups combined (combined Tx) were sexually active. A total of 20–30% of men in the AS group, 86–91% of men in the RP group, 56–60% of men in the RT group and 71–76% of men in the combined Tx group were sexually inactive as a result of erectile dysfunction. A total of 44–51% of men in the AS group, 96% of men in the RP group, 73–76% of men in the RT group and 84–85% of men in the combined Tx group who were sexually active had problems getting or keeping an erection. In multivariable analysis these differences were significant, except for AS vs RT. CONCLUSIONS: Men with localized PCa on AS were more often sexually active than similar men who received radical therapy, especially RP. If not sexually active, this was less often attributable to erectile dysfunction for those on AS. If sexually active, this was less often associated with problems getting or keeping an erection for those on AS. The study was non‐randomized; the latest advances in RP and RT might impact results.

Verified
Journal Article
Open access
PDF file
KBKATHARINA Beyer
KATHARINA Beyer
RLRenée C.A. Leenen
Renée C.A. Leenen
LVLionne Venderbos
Lionne Venderbos
JHJozien Helleman
Jozien Helleman
FDFréderique Béatrice Denijs
Fréderique Béatrice Denijs
OCon behalf of the PRAISE-U Consortium
on behalf of the PRAISE-U Consortium
With the new policy recommendation in 2022 to explore the possibilities of screening for prostate cancer by the European Commission, the landscape for prostate cancer early detection is evolving. In line with this recommendation, the PRAISE-U project aims to evaluate the early detection and diagnosis of prostate cancer through customised and risk-based screening programmes, with the goal to align protocols across European Union member states. This systematic review is part of the PRAISE-U project, with the goal to review the policy, medical guideline recommendations, and the current level of opportunistic screening presented in the scientific literature on prostate cancer early detection from 2016 to 2023 in European Union member states. An extensive literature search was performed on 1 June 2023 in a large number of databases, including Embase.com, Medline (Ovid), Web of Science Core Collection, Google Scholar, and Policy Commons. We identified 318 articles (qualitative, quantitative, and reviews), of which 41 were included in the full-text screening. Seventeen articles were ultimately identified as eligible for inclusion. The included articles revealed significant variations towards PSA-based early detection policies for prostate cancer in nine European countries. Despite official recommendations, opportunistic screening was prevalent across all nine countries regardless of recommendations for or against PSA-based early detection. This systematic review suggests that the current early detection policies are not fit for purpose. High levels of opportunistic screening and overdiagnosis persist, prompting policy recommendations for standardised guidelines, informed decision making, and increased awareness to improve efficiency and effectiveness in early detection.